Here is your pdf: BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors

The length of the document below is: 40 page(s) long

The self-declared author(s) is/are:
www.biorxiv.org

The subject is as follows:
Subject: Original authors did not specify.

The original URL is: LINK

The access date was:
Access date: 2019-04-01 16:01:18.497820

Please be aware that this may be under copyright restrictions. Please send an email to admin@pharmacoengineering.com for any AI-generated issues.

The content is as follows:

BRCA2 abrogation triggers innate immune responses potentiated by

treatment with

PARP inhibitor

s Timo Reisländer

1, Emilia Puig Lombardi

2,3,*, Florian

J.

Groelly

1,*, Ana

Miar

4, Manuela

Porru

5, Benjamin Wright

6, Helen Lockstone

6, Annamaria

Biroccio

5, Adrian Harris

4, Arturo Londono

2,3 and Madalena Tarsounas

1 1Genome Stability and Tumourigenesis

Group, The CR

-UK/MRC Oxford Institute for

Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus

Research Building, Oxford OX3 7DQ, U.K.

2Institut Curie, PSL Research University, CNRS, UMR3244, F

-75005, Paris, France.

3Sorbonne

Universités, UPMC Univ Paris 06, CNRS, UMR3244, F

-75005, Paris, France.

4Hypoxia and Angiogenesis Group, Weatherall Institute of Molecular Medicine,

Department of Oncology, University of Oxford, Oxford OX3 9DS, U.K.

5Area of Translational Research,

IRCCS

Regina Elena National Cancer Institute, 00144

Rome, Italy

6Bioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human

Genetics, University of Oxford, Oxford OX3 7BN, U.K.

*These authors contributed e

qually to this study.

*Correspondence:

madalena.tarsounas@oncology.ox.ac.uk

Please note all content on this page was automatically generated via our AI-based algorithm (BishopKingdom ID: 1rxtYWz5BGmogTraQvQS). Please let us know if you find any errors.